Generation Bio Co. (GBIO) | Investment Case

1. Company Snapshot

1.a. Company Description

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases.The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina.It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

The company was formerly known as Torus Therapeutics, Inc.and changed its name to Generation Bio Co. in November 2017.Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on GBIO

Generation Bio Co.'s recent performance was negatively impacted by a lack of significant advancements in its cell-targeted lipid nanoparticle (ctLNP) technology, which has been a key focus area for the company. The firm's revenue of $8.72 million in Q1 2025 fell short of analysts' expectations of $1.70 million, indicating a decline in sales. Additionally, the company's net margin of -782.86% and return on equity of -104.85% suggest significant operational challenges.

1.c. Company Highlights

Last Price	5.33
Change Percentage	2.11%
Open	5.3
Previous Close	5.22
Market Cap ( Millions)	36
Volume	21416
Year High	13.8
Year Low	3
M A 50	5.73
M A 200	4.89

FCF Yield	-227.47%
Dividend Yield	0.00%
ROE	-91.07%
Debt / Equity	157.71%
Net Debt / EBIDTA	-51.82%
Price To Book	0.66
Price Earnings Ratio	-0.49
Price To FCF	-0.44
Price To sales	1.69
EV / EBITDA	-1.03

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Generation Bio Announces Third Quarter 2025 Financial Results

Nov -05

Source: globenewswire.com

Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)

Oct -30

Source: defenseworld.net

Generation Bio Announces CEO Transition

Oct -22

Source: globenewswire.com

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Aug -12

Source: zacks.com

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Aug -12

Source: globenewswire.com

Generation Bio Announces 1-for-10 Reverse Stock Split

Jul -18

Source: globenewswire.com

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Jul -07

Source: globenewswire.com

Squarepoint Ops LLC Takes Position in Generation Bio Co. (NASDAQ:GBIO)

Jun -11

Source: https://www.defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.00%)

6. Segments

Genetic Medicines

Expected Growth: 3.0%

Generation Bio Co.'s Genetic Medicines segment growth is driven by increasing adoption of gene therapies, rising prevalence of genetic disorders, and advancements in gene editing technologies like CRISPR. Additionally, partnerships with pharmaceutical companies and investments in manufacturing capabilities are expected to fuel growth, resulting in a 3.0 growth rate.

7. Detailed Products

Cell Therapy

Generation Bio Co.'s cell therapy products utilize genetically modified cells to treat various diseases and disorders.

Gene Therapy

Generation Bio Co.'s gene therapy products involve the use of genes to prevent or treat diseases.

Gene Editing

Generation Bio Co.'s gene editing products utilize CRISPR-Cas9 technology to edit genes and treat genetic disorders.

RNA-Based Therapies

Generation Bio Co.'s RNA-based therapies products utilize RNA molecules to treat various diseases and disorders.

Vaccine Development

Generation Bio Co.'s vaccine development products utilize genetic engineering to develop vaccines against infectious diseases.

8. Generation Bio Co.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Generation Bio Co. has a moderate threat of substitutes due to the presence of alternative gene therapies and treatments for genetic diseases.

Bargaining Power Of Customers

Generation Bio Co. has a low bargaining power of customers due to the lack of alternative treatments for rare genetic diseases, giving patients limited options.

Bargaining Power Of Suppliers

Generation Bio Co. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment, but limited options for specialized services.

Threat Of New Entrants

Generation Bio Co. has a high threat of new entrants due to the growing interest in gene therapy and the potential for new companies to enter the market with innovative technologies.

Intensity Of Rivalry

Generation Bio Co. operates in a highly competitive market with several established players, leading to a high intensity of rivalry among companies.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	32.52%
Debt Cost	12.21%
Equity Weight	67.48%
Equity Cost	18.29%
WACC	16.31%
Leverage	48.19%

11. Quality Control: Generation Bio Co. passed 3 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Arcutis Bio

A-Score: 5.0/10

Value: 6.2

Growth: 7.0

Quality: 5.5

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

VBI Vaccines

A-Score: 3.9/10

Value: 9.8

Growth: 6.1

Quality: 2.4

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

Bolt Biotherapeutics

A-Score: 3.7/10

Value: 9.6

Growth: 6.9

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

MacroGenics

A-Score: 3.3/10

Value: 8.4

Growth: 6.0

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

Lyell Immunopharma

A-Score: 3.2/10

Value: 7.6

Growth: 1.0

Quality: 4.7

Yield: 0.0

Momentum: 5.5

Volatility: 0.7

1-Year Total Return ->

Generation Bio

A-Score: 3.2/10

Value: 8.6

Growth: 5.4

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

18.50%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

16.31%

Generation Bio Co. - US37148K1007

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on GBIO

1.c. Company Highlights

Average Growth

Medium Volatility

Average Quality

Earnings Miss

Revenues Beats

More Volatile

Stable Momentum

Lower Growth

Earnings Beats

Fairly Valued

Cheaper

Weak Momentum

Revenues Miss

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.00%)

6. Segments

Genetic Medicines

Expected Growth: 3.0%

7. Detailed Products

Cell Therapy

Gene Therapy

Gene Editing

RNA-Based Therapies

Vaccine Development

8. Generation Bio Co.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Generation Bio Co. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.33$

Current Price

5.33$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA